Rónán C. O’Hagan

4.8k citations

30 papers · 3.1k indexed · 1 hit paper · h-index 18

Molecular Biology top 5%
Oncology top 2%
Cancer Research top 5%
Physiology top 5%
Genetics top 10%

Co-authors: Ronald A. DePinho Lynda Chin Frederick W. Alt Ignacio Moreno de Alborán Laurie A. Davidson Barbara A. Malynn John A. Hassell James W. Horner
Topics: Ubiquitin and proteasome pathways (5 papers)Cancer-related Molecular Pathways (5 papers)Monoclonal and Polyclonal Antibodies Research (4 papers)
Cited by: Oncology Molecular Biology Aging
Journals: Nature Proceedings of the National Academy of Sciences Nature Genetics
Partner nations: United States Canada Brazil

In The Last Decade

Rónán C. O’Hagan

29 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Essential role for oncogenic Ras in tumour maintenance

1999 697 citations Lynda Chin, Jason H. Pomerantz et al. Nature profile →

Peers

Countries citing papers authored by Rónán C. O’Hagan

Since Specialization

Citations

This map shows the geographic impact of Rónán C. O’Hagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rónán C. O’Hagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rónán C. O’Hagan more than expected).

Fields of papers citing papers by Rónán C. O’Hagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rónán C. O’Hagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rónán C. O’Hagan. The network helps show where Rónán C. O’Hagan may publish in the future.

Co-authorship network of co-authors of Rónán C. O’Hagan

This figure shows the co-authorship network connecting the top 25 collaborators of Rónán C. O’Hagan. A scholar is included among the top collaborators of Rónán C. O’Hagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rónán C. O’Hagan. Rónán C. O’Hagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown),Miso Park,Magali Pederzoli-Ribeil,Uğur Eskiocak,(unknown),(unknown),M. A. McLaughlin,(unknown),(unknown),Zhen Liu,Benjamin Nicholson,(unknown),Huawei Qiu,Tim Clackson,Rónán C. O’Hagan,Ulrich Rodeck,Margaret Karow,Jennifer O’Neil,John C. Williams	8
2	A Study Design to Harmonize Patient-Reported Outcomes Across Data Sets 2023 ·JCO Clinical Cancer Informatics ·(unknown),Alexandra Berk,Lynda Chin,Stacie Hudgens,Ian Kudel,Rónán C. O’Hagan,(unknown),(unknown),(unknown),Sam C. Wang,Debra Wujcik,Mark Stewart,Jeff Allen	3
3	Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates. 2021 ·Journal of Clinical Oncology ·Jennifer O’Neil,(unknown),(unknown),(unknown),Manoussa Fanny,Justin Greene,Megan McLaughlin,(unknown),Rebekah K. O’Donnell,Huawei Qiu,Benjamin Nicholson,William Avery,Rónán C. O’Hagan	15
4	587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models 2020 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),Minjie Zhang,(unknown),Uğur Eskiocak,M. A. McLaughlin,(unknown),Magali Pederzoli-Ribeil,Miso Park,John C. Williams,Margaret Karow,Jennifer O’Neil,Timothy Piers Clackson,Rónán C. O’Hagan	2
5	Identification of Kinases Responsible for p53-Dependent Autophagy 2019 ·iScience ·Stephanie L. Celano,Lisette Yco,(unknown),(unknown),Hakan Günaydin,M.L. Scott,E. T. C. Spooner,Rónán C. O’Hagan,Peter H. Fuller,Katie R. Martin,Stuart D. Shumway,Jeffrey P. MacKeigan	4
6	A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress 2018 ·iScience ·Katie R. Martin,Stephanie L. Celano,(unknown),Hakan Günaydin,M.L. Scott,Rónán C. O’Hagan,Stuart D. Shumway,Peter H. Fuller,Jeffrey P. MacKeigan	139
7	23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity 2015 ·Molecular Cancer Therapeutics ·Theresa A. Proia,Feng Jiang,(unknown),Richard Nicoletti,Lingxin Kong,(unknown),Laura L. Poling,William M. Winston,(unknown),Solly Weiler,(unknown),Rónán C. O’Hagan,Jie Lin,Jenő Gyuris,Heidi Okamura	8
8	Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status 2015 ·Cancer Cell International ·Sybil M. Genther Williams,(unknown),Paula B. Andrade,Brian Dolinski,Cem Elbi,Rónán C. O’Hagan,Carlo Toniatti	31
9	KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations 2011 ·Genes & Cancer ·Rónán C. O’Hagan,Joerg Heyer	24
10	Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model 2003 ·Proceedings of the National Academy of Sciences ·Karuppiah Kannan,Norman E. Sharpless,Jin Xu,Rónán C. O’Hagan,Marcus Bosenberg,Lynda Chin	90
11	Telomere dysfunction provokes regional amplification and deletion in cancer genomes 2002 ·Cancer Cell ·Rónán C. O’Hagan,Sandy Chang,Richard S. Maser,(unknown),Steven E. Artandi,Lynda Chin,Ronald A. DePinho	182
12	Impaired Nonhomologous End-Joining Provokes Soft Tissue Sarcomas Harboring Chromosomal Translocations, Amplifications, and Deletions 2001 ·Molecular Cell ·Norman E. Sharpless,David O. Ferguson,Rónán C. O’Hagan,Diego H. Castrillón,Charles Lee,Paraskevi A. Farazi,(unknown),James C. Fleming,Cynthia C. Morton,Karen M. Frank,Lynda Chin,Frederick W. Alt,Ronald A. DePinho	133
13	Analysis of C-MYC Function in Normal Cells via Conditional Gene-Targeted Mutation 2001 ·Immunity ·Ignacio Moreno de Alborán,Rónán C. O’Hagan,Fátima Gärtner,Barbara A. Malynn,Laurie A. Davidson,Robert C. Rickert,Klaus Rajewsky,Ronald A. DePinho,Frederick W. Alt	319
14	Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression 2000 ·Genes & Development ·Rónán C. O’Hagan,Michael Ohh,Gregory David,Ignacio Moreno de Alborán,Frederick W. Alt,William G. Kaelin,Ronald A. DePinho	163
15	Gene-target recognition among members of the Myc superfamily and implications for oncogenesis 2000 ·Nature Genetics ·Rónán C. O’Hagan,Nicole Schreiber‐Agus,Ken Chen,Gregory David,Jeffrey A. Engelman,Richard B. Schwab,Leila Alland,Cole T. Thomson,Donald R. Ronning,James C. Sacchettini,Paul S. Meltzer,Ronald A. DePinho	120
16	Essential role for oncogenic Ras in tumour maintenancebreakdown → 1999 ·Nature ·Lynda Chin,(unknown),Jason H. Pomerantz,Michelle Wong,Jocelyn Holash,Nabeel Bardeesy,Qiong Shen,Rónán C. O’Hagan,(unknown),(unknown),James W. Horner,Carlos Cordon-Cardo,George D. Yancopoulos,Ronald A. DePinho	697
17	Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation 1999 ·Oncogene ·Roger A. Greenberg,Rónán C. O’Hagan,Hongyu Deng,Qiurong Xiao,(unknown),Robert R. Adams,Serge Lichtsteiner,Lynda Chin,Gregg B. Morin,Ronald A. DePinho	344
18	The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase 1998 ·Oncogene ·Rónán C. O’Hagan,John A. Hassell	62
19	HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer 1997 ·Oncogene ·Christopher C. Benz,Rónán C. O’Hagan,B. Diane Richter,Gary K. Scott,Chuan-Hsiung Chang,Xiaohui Xiong,Karen Chew,Britt‐Marie Ljung,Susan M. Edgerton,Ann D. Thor,John A. Hassell	142
20	The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. 1996 ·PubMed ·Rónán C. O’Hagan,Richard Tozer,Marc Symons,Frank McCormick,John A. Hassell	126

About Rónán C. O’Hagan

Rónán C. O’Hagan is a scholar working on Oncology, Biotechnology and Immunology and Allergy, having authored 30 papers that have together received 3.1k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (5 papers), Cancer-related Molecular Pathways (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Oncology (1.1k citations), Molecular Biology (2.2k citations) and Aging (55 citations). Rónán C. O’Hagan has collaborated with scholars based in United States, Canada and Brazil. Frequent co-authors include Ronald A. DePinho, Lynda Chin, Frederick W. Alt, Ignacio Moreno de Alborán, Laurie A. Davidson, Barbara A. Malynn, John A. Hassell, James W. Horner, Jason H. Pomerantz and Qiong Shen. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact